Cognitive Screening in Lung Cancer Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorEuropean Institute of Oncology
About this trial
This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.
Eligibility criteria
Qualifiers
Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
Age ≥ 18 years
Patients able to speak and read the local language(s) fluently
Acceptance and signature of informed consent
Disqualifiers
Age ≥ 70
Presence of brain metastases
Patients with concomitant neurological or psychiatric disorders.
Patients undergoing brain radiotherapy
Trial design
Treatments tested in this trial
- Not listed
Trial groups
200 Participants
are grouped into 1 trial groupLocations
1Istituto Europeo di Oncologia20141, Milan Italy
Sponsors and collaborators
European Institute of Oncology
Lead sponsor
Source ClinicalTrials.gov